Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease (ESRD) and is therefore a major burden on the healthcare system. Patients with DKD are highly susceptible to developing cardiovascular disease, which contributes to increased morbidity and mortality rates. While progress has been made to inhibit the acceleration of DKD, current standards of care reduce but do not eliminate the risk of DKD. There is growing appreciation for the role of inflammation in modulating the process of DKD. The focus of this review is on providing an overview of the current status of knowledge regarding the pathologic roles of inflammation in the development of DKD. Finally, we summarize recent therapeutic advances to prevent DKD, with a focus on the anti-inflammatory effects of newly developed agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 1×
“Importantly, this trial showed no imbalance in rates of amputation or bone fracture, and no new safety concerns were identified [53].”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 1×
“For example, the renal composite outcomes (doubling of creatinine, renal replacement therapy, or renal death) decreased by 46% in patients with type 2 diabetes treated with empagliflozin [52].”
BackgroundNrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 1×
“reported that Nrf2 binds to the regulatory regions of inflammatory genes and thereby induces their transcription in macrophages and alleviates RNA polymerase II recruitment [37].”
BackgroundAdler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W., Cull, C. A., Holman, R. R., & UKPDS Group (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00712.x · Cited by 1,816
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Transcriptome Analysis of Human Diabetic Kidney Disease
Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., & Susztak, K. (2011) · Diabetes · doi:10.2337/db10-1181 · Cited by 642
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493
Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
Niewczas, M. A., Gohda, T., Skupien, J., Smiles, A. M., Walker, W. H., Rosetti, F., Cullere, X., Eckfeldt, J. H., Doria, A., Mayadas, T. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060627 · Cited by 485
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483 · cited 6×
“Experimental studies have also suggested the anti-inflammatory effects of SGLT2 inhibitors [56,57].”
BackgroundInfluentialHeerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Inflammation in Diabetic Nephropathy
Lim, A. K. H., & Tesch, G. H. (2012) · Mediators of Inflammation · doi:10.1155/2012/146154 · Cited by 437
Niewczas, M. A., Pavkov, M. E., Skupien, J., Smiles, A., Md Dom, Z. I., Wilson, J. M., Park, J., Nair, V., Schlafly, A., Saulnier, P.-J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0415-5 · Cited by 432
Ganesh Yerra, V., Negi, G., Sharma, S. S., & Kumar, A. (2013) · Redox Biology · doi:10.1016/j.redox.2013.07.005 · Cited by 412
Vasamsetti, S. B., Karnewar, S., Kanugula, A. K., Thatipalli, A. R., Kumar, J. M., & Kotamraju, S. (2015) · Diabetes · doi:10.2337/db14-1225 · Cited by 397 · cited 1×
“By activating AMPK, metformin disrupts the phosphorylation of STAT signaling and attenuates the differentiation of monocytes into macrophages [73].”
BackgroundKodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 1×
“Albuminuria and mesangial expansion were attenuated by treatment with exenatide in streptozotocin-injected type 1 diabetic rats through a mechanism involving inflammatory cytokines and adhesion molecules [69].”
BackgroundThe actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 348
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Eller, K., Kirsch, A., Wolf, A. M., Sopper, S., Tagwerker, A., Stanzl, U., Wolf, D., Patsch, W., Rosenkranz, A. R., & Eller, P. (2011) · Diabetes · doi:10.2337/db11-0358 · Cited by 318
AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions
Sanajou, D., Ghorbani Haghjo, A., Argani, H., & Aslani, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.001 · Cited by 313
Inflammation in Diabetic Kidney Disease
Pérez-Morales, R. E., del Pino, M. D., Valdivielso, J. M., Ortiz, A., Mora-Fernández, C., & Navarro-González, J. F. (2019) · Nephron · doi:10.1159/000493278 · Cited by 304
Okada, S., Shikata, K., Matsuda, M., Ogawa, D., Usui, H., Kido, Y., Nagase, R., Wada, J., Shikata, Y., & Makino, H. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2586 · Cited by 298
Pichler, R., Afkarian, M., Dieter, B. P., & Tuttle, K. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2016 · Cited by 295
Tuttle, K. R., Brosius, F. C., Adler, S. G., Kretzler, M., Mehta, R. L., Tumlin, J. A., Tanaka, Y., Haneda, M., Liu, J., Silk, M. E., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx377 · Cited by 284
Doupis, J., Lyons, T. E., Wu, S., Gnardellis, C., Dinh, T., & Veves, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2385 · Cited by 266
Garvey, W. T., Van Gaal, L., Leiter, L. A., Vijapurkar, U., List, J., Cuddihy, R., Ren, J., & Davies, M. J. (2018) · Metabolism · doi:10.1016/j.metabol.2018.02.002 · Cited by 261
Inflammation as a Therapeutic Target for Diabetic Neuropathies
Pop-Busui, R., Ang, L., Holmes, C., Gallagher, K., & Feldman, E. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0727-5 · Cited by 259
Macrophages in diabetic nephropathy in patients with type 2 diabetes
Klessens, C. Q. F., Zandbergen, M., Wolterbeek, R., Bruijn, J. A., Rabelink, T. J., Bajema, I. M., & IJpelaar, D. H. T. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw260 · Cited by 244
Park, C. W., Kim, H. W., Ko, S. H., Lim, J. H., Ryu, G. R., Chung, H. W., Han, S. W., Shin, S. J., Bang, B. K., Breyer, M. D., et al. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070778 · Cited by 218 · cited 1×
“For instance, exenatide was shown to inhibit albuminuria and the influx of glomerular macrophages in type 2 diabetic db/db mice [68].”
BackgroundPollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M., & Heerspink, H. J. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30086-5 · Cited by 205
Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Więcek, A., Haller, H., & for the Emapticap Study Group (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv459 · Cited by 201
Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes
Utimura, R., Fujihara, C. K., Mattar, A. L., Malheiros, D. M. A. C., de Lourdes Noronha, I., & Zatz, R. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00736.x · Cited by 196
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
Toth-Manikowski, S., & Atta, M. G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/697010 · Cited by 192
Kröller-Schön, S., Knorr, M., Hausding, M., Oelze, M., Schuff, A., Schell, R., Sudowe, S., Scholz, A., Daub, S., Karbach, S., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs246 · Cited by 174
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., & Utsunomiya, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051083 · Cited by 168
Self-citationWEIGERT, C., SAUER, U., BRODBECK, K., PFEIFFER, A., HA[Combining Diaeresis]RING, H. U., & SCHLEICHER, E. D. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11112007 · Cited by 165
Clausen, P., Jacobsen, P., Rossing, K., Jensen, J. S., Parving, H. ‐., & Feldt‐Rasmussen, B. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00347.x · Cited by 150
Ferdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E. M., Sager, P. T., Brunelle, R., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 145
Devaraj, S., Tobias, P., Kasinath, B. S., Ramsamooj, R., Afify, A., & Jialal, I. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.228924 · Cited by 141
Barbieri, M., Rizzo, M. R., Marfella, R., Boccardi, V., Esposito, A., Pansini, A., & Paolisso, G. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.018 · Cited by 136
Kanasaki, K. (2018) · Clinical Science · doi:10.1042/cs20180031 · Cited by 117
Nadkarni, G. N., Rao, V., Ismail-Beigi, F., Fonseca, V. A., Shah, S. V., Simonson, M. S., Cantley, L., Devarajan, P., Parikh, C. R., & Coca, S. G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12051115 · Cited by 114
Nuclear Rho Kinase, ROCK2, Targets p300 Acetyltransferase
Tanaka, T., Nishimura, D., Wu, R.-C., Amano, M., Iso, T., Kedes, L., Nishida, H., Kaibuchi, K., & Hamamori, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510954200 · Cited by 114
M1/M2 Macrophages in Diabetic Nephropathy: Nrf2/HO-1 as Therapeutic Targets
Landis, R. C., Quimby, K. R., & Greenidge, A. R. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180716163845 · Cited by 113
Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice
Zhang, H., Nair, V., Saha, J., Atkins, K. B., Hodgin, J. B., Saunders, T. L., Myers, M. G., Werner, T. B., Kretzler, M., & Brosius, F. C. (2017) · Kidney International · doi:10.1016/j.kint.2017.03.027 · Cited by 107
Lenda, D. M., Kikawada, E., Stanley, E. R., & Kelley, V. R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3254 · Cited by 103
Matoba, K., Kawanami, D., Okada, R., Tsukamoto, M., Kinoshita, J., Ito, T., Ishizawa, S., Kanazawa, Y., Yokota, T., Murai, N., et al. (2013) · Kidney International · doi:10.1038/ki.2013.130 · Cited by 103
Self-citationMuskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12601 · Cited by 102
Lim, A. K. H., Ma, F. Y., Nikolic‐Paterson, D. J., Thomas, M. C., Hurst, L., & Tesch, G. H. (2009) · Diabetologia · doi:10.1007/s00125-009-1399-3 · Cited by 102
Signaling pathways in diabetic nephropathy.
Kawanami, D., Matoba, K., & Utsunomiya, K. (2016) · PubMed · doi:10.14670/hh-11-777 · Cited by 99
Self-citationShimada, H., & Rajagopalan, L. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.099630 · Cited by 98
Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology
Simó‐Servat, O., Simó, R., & Hernández, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5263798 · Cited by 97
Usui, H. K., Shikata, K., Sasaki, M., Okada, S., Matsuda, M., Shikata, Y., Ogawa, D., Kido, Y., Nagase, R., Yozai, K., et al. (2007) · Diabetes · doi:10.2337/db06-0359 · Cited by 91
Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
Pena, M. J., Mischak, H., & Heerspink, H. J. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4001-9 · Cited by 89
Critical role for osteopontin in diabetic nephropathy
Nicholas, S. B., Liu, J., Kim, J., Ren, Y., Collins, A. R., Nguyen, L. N. T., & Hsueh, W. A. (2010) · Kidney International · doi:10.1038/ki.2009.518 · Cited by 88
Zhao, D., Kuhnt-Moore, S., Zeng, H., Wu, J. S., Moyer, M. P., & Pothoulakis, C. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00328.2002 · Cited by 86
Toshinobu, M. A. K. I., Maeno, S., Maeda, Y., Yamato, M., Sonoda, N., Ogawa, Y., Wakisaka, M., & Inoguchi, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-41253-7 · Cited by 82
Lázaro, I., Lopez‐Sanz, L., Bernal, S., Oguiza, A., Recio, C., Melgar, A., Jiménez-Castilla, L., Egido, J., Madrigal‐Matute, J., & Gómez‐Guerrero, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00819 · Cited by 78
Satirapoj, B., Dispan, R., Radinahamed, P., & Kitiyakara, C. (2018) · BMC Nephrology · doi:10.1186/s12882-018-1043-x · Cited by 75
Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: A prospective study
Verhave, J. C., Bouchard, J., Goupil, R., Pichette, V., Brachemi, S., Madore, F., & Troyanov, S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.07.006 · Cited by 72
Hojs, R., Ekart, R., Bevc, S., & Hojs, N. V. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447434 · Cited by 70
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., & Nangaku, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00590.2014 · Cited by 69
Xu, L., Lin, X., Guan, M., Zeng, Y., & Liu, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/1896041 · Cited by 68
Dose- and time-dependent glucocorticoid receptor signaling in podocytes
Guess, A. J., Agrawal, S., Wei, C., Ransom, R. F., Benndorf, R., & Smoyer, W. E. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00161.2010 · Cited by 66
Macrophage Growth Factors Introduced into the Kidney Initiate Renal Injury
Naito, T., Yokoyama, H., Moore, K. J., Dranoff, G., Mulligan, R. C., & Kelley, V. R. (1996) · Molecular Medicine · doi:10.1007/bf03401628 · Cited by 64
Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat
Rodríguez‐Iturbe, B., Quiroz, Y., Shahkarami, A., Li, Z., & Vaziri, N. D. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00496.x · Cited by 63
Macrophage polarization in kidney diseases
Tian, S., & Chen, S. (2015) · Macrophage · doi:10.14800/macrophage.679 · Cited by 60
Meyer‐Schwesinger, C., Dehde, S., von Ruffer, C., Gatzemeier, S., Klug, P., Wenzel, U. O., Stahl, R. A. K., Thaiss, F., & Meyer, T. N. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90746.2008 · Cited by 60
Liu, J., Yeoh, L. Y., Sum, C. F., Subramaniam, T., Ng, X. W., Liu, S., Lee, S. B. M., Tang, W. E., & Lim, S. C. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.02.011 · Cited by 59
ROCK2 Regulates Monocyte Migration and Cell to Cell Adhesion in Vascular Endothelial Cells
Takeda, Y., Matoba, K., Kawanami, D., Nagai, Y., Akamine, T., Ishizawa, S., Kanazawa, Y., Yokota, T., & Utsunomiya, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061331 · Cited by 55
Self-citationTahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.019 · Cited by 53
Kawanami, D., Matoba, K., Kanazawa, Y., Ishizawa, S., Yokota, T., & Utsunomiya, K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.031 · Cited by 50
Self-citationMatoba, K., Kawanami, D., Tsukamoto, M., Kinoshita, J., Ito, T., Ishizawa, S., Kanazawa, Y., Yokota, T., Murai, N., Matsufuji, S., et al. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00113.2014 · Cited by 50
Self-citationIncretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
Self-citationThe Role of Iron and Nerve Inflammation in Diabetes Mellitus Type 2-Induced Peripheral Neuropathy
Paeschke, S., Baum, P., Toyka, K. V., Blüher, M., Koj, S., Klöting, N., Bechmann, I., Thiery, J., Kosacka, J., & Nowicki, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.005 · Cited by 32
Wu, C., Qin, N., Ren, H., Yang, M. H., Liu, S., & Wang, Q. (2018) · International Journal of Endocrinology · doi:10.1155/2018/6462793 · Cited by 24
Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice
Seo, J.-W., Kim, Y., Lee, S. H., Lee, A., Kim, D.-J., Jeong, K. H., Lee, K. H., Hwang, S. J., Woo, J. S., Lim, S. J., et al. (2015) · BioMed Research International · doi:10.1155/2015/301627 · Cited by 18
The Promise of Systems Biology for Diabetic Kidney Disease
Brosius, F. C., & Ju, W. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.012 · Cited by 16
Kawanami, D., Matoba, K., Okada, R., Tsukamoto, M., Kinoshita, J., Ishizawa, S., Kanazawa, Y., Yokota, T., & Utsunomiya, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.091 · Cited by 15
Self-citation
Cited by
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Lu, X., Xie, Q., Pan, X., Zhang, R., Zhang, X., Peng, G., Zhang, Y., Shen, S., & Tong, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01951-9 · Cited by 665
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy
Yang, J., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816400 · Cited by 281
Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives
Tanase, D. M., Gosav, E. M., Anton, M. I., Floria, M., Seritean Isac, P. N., Hurjui, L. L., Tarniceriu, C. C., Costea, C. F., Ciocoiu, M., & Rezus, C. (2022) · Biomolecules · doi:10.3390/biom12091227 · Cited by 198
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Metadata
- Authors
- Matoba, K., Takeda, Y., Nagai, Y., Kawanami, D., Utsunomiya, K., & Nishimura, R.
- Affiliations
- Jikei University School of Medicine (JP)
- Fukuoka University (JP)
- Corresponding author
- Matoba, Keiichiro
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-07-10
- Volume
- 20
- Issue
- 14
- Pages
- 3393
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6678414
- OpenAlex
- W2958949191
- Semantic Scholar
- 1919f7691771fef371eec317a2f8802ae08a78f7
- Cited by
- 223
- References
- 84
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 40 · 2023: 26 · 2022: 44 · 2021: 36 · 2020: 22 · 2019: 5
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science (18K15985)
- Ichiro Kanehara Foundation (N/A)
- MSD Life Science Foundation (N/A)
- Yokoyama Foundation for Clinical Pharmacology (N/A)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- diabetic nephropathy, inflammation, pathogenesis, end-stage renal disease, cardiovascular disease, anti-inflammatory therapy, novel therapeutic agents
- MeSH terms
- Animals, Diabetic Nephropathies, Disease Susceptibility, Humans, Inflammation, Signal Transduction, Biomarkers, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.